Mutation-Blocking Drug Combined With Immunotherapy Shows Promise in Lung Cancer

Lung cancer kills approximately 1.8 million people annually worldwide, with only 25% of patients surviving more than five years after diagnosis.

Each year, lung cancer quietly claims 1.8 million lives — a toll that has long resisted medicine's best efforts. Now, researchers at the Francis Crick Institute in London have identified a conditional but meaningful breakthrough: pairing a drug that silences a rogue genetic mutation called KRAS with immunotherapy may successfully control certain lung cancers, specifically those whose tumors already hum with immune activity. The discovery is less a cure than a map — one that tells scientists not only where a promising path may lie, but also where previous clinical trials may have wandered off c

Mutation-Blocking Drug Combined With Immunotherapy Shows Promise in Lung Cancer

Cobertura Relacionada

Recibe The Register en tu bandeja